MNKD (Mannkind Corporation)
Insider Trading Activity
Every open-market purchase and sale reported by MNKD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-10 | Steven B. Binder | Director | Sell | — | — |
| 2026-07-17 | Dominic Marasco | Pres, Endocrine Business Unit | F | — | — |
| 2026-07-17 | Sanjay R Singh | EVP Technical Operations | MIXED | — | — |
| 2026-07-17 | Michael Castagna | Chief Executive Officer | MIXED | — | — |
| 2026-07-17 | Christopher B Prentiss | Chief Financial Officer | F | — | — |
| 2026-07-17 | Stuart A Tross | Chief People & Workpl Officer | MIXED | — | — |
| 2026-07-17 | Steven B. Binder | Director | MIXED | — | — |
| 2026-07-17 | David Thomson | EVP Genl Counsel & Secretary | MIXED | — | — |
| 2026-05-22 | Stuart A Tross | Chief People & Workpl Officer | A | — | — |
| 2026-05-22 | ANTHONY C HOOPER | Director | A | — | — |
| 2026-05-22 | Michael A Friedman | Director | A | — | — |
| 2026-05-22 | Jennifer Grancio | Director | A | — | — |
| 2026-05-22 | Sabrina Kay | Director | A | — | — |
| 2026-05-22 | Steven B. Binder | Director | A | — | — |
| 2026-05-22 | Ronald J Consiglio | Director | A | — | — |
| 2026-05-22 | James Samuel Shannon | Director | A | — | — |
| 2026-05-22 | CHRISTINE MUNDKUR | Director | A | — | — |
| 2026-05-22 | Dominic Marasco | Pres, Endocrine Business Unit | A | — | — |
| 2026-05-13 | David Thomson | EVP Genl Counsel & Secretary | MIXED | — | — |
| 2026-05-13 | Stuart A Tross | Chief People & Workpl Officer | F | — | — |
| 2026-05-13 | Steven B. Binder | Director | MIXED | — | — |
| 2026-05-13 | Michael Castagna | Chief Executive Officer | F | — | — |
| 2026-05-08 | Michael Castagna | Chief Executive Officer | — | — | — |
| 2026-04-24 | Christopher B Prentiss | Chief Financial Officer | F | — | — |
| 2026-03-25 | Michael Castagna | Chief Executive Officer | A | — | — |
| 2026-03-25 | Christopher B Prentiss | Chief Financial Officer | A | — | — |
| 2026-03-25 | Ajay Ahuja | Chief Medical Officer | A | — | — |
| 2026-03-25 | David Thomson | EVP Genl Counsel & Secretary | A | — | — |
| 2026-03-25 | Sanjay R Singh | EVP Technical Operations | A | — | — |
| 2026-03-25 | Stuart A Tross | Chief People & Workpl Officer | A | — | — |
| 2026-03-10 | Michael Castagna | Chief Executive Officer | Buy | — | — |
| 2026-03-03 | ANTHONY C HOOPER | Director | A | — | — |
| 2026-03-03 | James Samuel Shannon | Director | A | — | — |
| 2026-03-03 | Christopher B Prentiss | Chief Financial Officer | A | — | — |
| 2026-03-02 | Michael Castagna | Chief Executive Officer | A | — | — |
| 2026-03-02 | David Thomson | EVP Genl Counsel & Secretary | A | — | — |
| 2026-03-02 | Steven B. Binder | Director | A | — | — |
| 2026-03-02 | Stuart A Tross | Chief People & Workpl Officer | A | — | — |
| 2026-01-09 | Stuart A Tross | Chief People & Workpl Officer | Sell | — | — |
| 2025-12-29 | Michael Castagna | Chief Executive Officer | G | — | — |
| 2025-12-19 | Michael Castagna | Chief Executive Officer | MIXED | — | — |
| 2025-12-16 | Michael Castagna | Chief Executive Officer | MIXED | — | — |
| 2025-12-04 | Michael Castagna | Chief Executive Officer | MIXED | — | — |
| 2025-12-04 | David Thomson | EVP Genl Counsel & Secretary | MIXED | — | — |
| 2025-11-14 | Sanjay R Singh | EVP Technical Operations | Sell | — | — |
| 2025-11-12 | Ajay Ahuja | Chief Medical Officer | A | — | — |
| 2025-11-03 | Sanjay R Singh | EVP Technical Operations | F | — | — |
| 2025-09-17 | Stuart A Tross | Chief People & Workpl Officer | Sell | — | — |
| 2025-08-06 | Stuart A Tross | Chief People & Workpl Officer | A | — | — |
| 2025-07-17 | Lauren M Sabella | EVP Operations | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 2,605,660 | — |
| — | Chief People & Workpl Officer | 1,058,142 | — |
| — | Executive Chairman | 1,007,702 | — |
| — | EVP Genl Counsel & Secretary | 868,457 | — |
| — | Director | 785,867 | — |
| — | EVP Endocrine Business Unit | 781,690 | — |
| — | Chief Technology Officer | 745,233 | — |
| — | Director | 512,130 | — |
| — | EVP Technical Operations | 478,966 | — |
| — | EVP Chief Medical Officer | 460,791 | — |
| — | EVP Operations | 349,841 | — |
| — | Pres, Endocrine Business Unit | 343,398 | — |
| — | Chief Financial Officer | 318,668 | — |
| — | Chief Medical Officer | 318,200 | — |
| — | Director | 236,153 | — |
| — | President & CEO | 222,868 | — |
| — | VP, IR & Treasury | 167,119 | — |
| — | Director | 132,342 | — |
| — | Director | 110,701 | — |
| — | Director | 107,033 | — |
| — | Chief Commercial Officer | 83,972 | — |
| — | CEO, CFO, Director | 81,961 | — |
| — | Chief Marketing Officer | 43,012 | — |
| — | Corporate VP | 41,318 | — |
| — | Chief Medical Officer | 41,059 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MNKD quote page; the site-wide leaderboard is on the insider transactions hub.